Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
|Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.|
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
Receive an email update when we add a new PULMONARY FIBROSIS article.
The Latest on: Pulmonary fibrosis
via Google News
The Latest on: Pulmonary fibrosis
- ‘Curb air pollution to cut pulmonary diseases’ on December 4, 2018 at 2:52 pm
I am particularly excited about advances in lung transplant programmes, new treatment for pulmonary fibrosis, robotic bronchoscopy and endobronchial valve for emphysema in recent years,” said ... […]
- Global Idiopathic Pulmonary Fibrosis Market Projected huge Growth by 2023: Leading Companies, Opportunities, Drivers, Challenges, & Forecast on December 2, 2018 at 6:03 am
In depth analysis of an industry is a crucial thing for various stakeholders like investors, CEOs, traders, suppliers and others. The Global Aflatoxicosis Treatment industry 2018 market research repor... […]
- Redx Pharma's first candidate RXC006 data suggests great potential for treatment of fibrosis on December 1, 2018 at 12:30 am
RXC006, a novel inhibitor of the porcupine enzyme, will be developed as an orally administered, first-in-class treatment for the orphan disease, idiopathic pulmonary fibrosis (IPF). IPF is a severe an... […]
- Redx Pharma looks for some Porcupine help in its fight against cancer and fibrosis on November 30, 2018 at 3:30 am
The Wnt pathway is widely believed to be heavily involved in the tissue scarring process which is typical of idiopathic pulmonary fibrosis. “The second leg of the company is the whole area of fibrosis ... […]
- Redx Pharma Drug Candidate RXC006 To Be Developed As Fibrosis Drug on November 30, 2018 at 3:25 am
LONDON (Alliance News) - Drug developer Redx Pharma PLC said Friday its RXC006 drug candidate was able to suppress lung fibrosis in living organisms and will be developed as a treatment for idiopathic ... […]
- Redx Pharma jumps as first data shows 'great potential' for fibrosis candidate on November 30, 2018 at 1:31 am
Trials with the drug have successfully suppressed both liver and kidney fibrosis in animal models and led to a reduction in collagen deposition and severity of pulmonary fibrosis in two mouse models. ... […]
- Redx Pharma presents positive pre-clinical data on fibrosis treatment on November 30, 2018 at 12:17 am
StockMarketWire.com - Redx Pharma said it had presented pre-clinical data at a US conference for a new drug development candidate to treat idiopathic pulmonary fibrosis, a long condition. Data on cand... […]
- Global Idiopathic Pulmonary Fibrosis Market Revenue Status and Outlook (2013-2025) on November 18, 2018 at 6:34 pm
Global Idiopathic Pulmonary Fibrosis Market Research Report 2018 contains historic data that spans 2013 to 2017, and then continues to forecast to 2025. That makes this report so invaluable, resources ... […]
- Europe Idiopathic Pulmonary Fibrosis Market and Competitive Landscape - 2018 - ResearchAndMarkets.com on November 15, 2018 at 2:26 pm
DUBLIN--(BUSINESS WIRE)--The "Europe Idiopathic Pulmonary Fibrosis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Europe Idiopathic Pulmonary Fibr... […]
via Bing News